BMF Capital questions SELLAS Life Sciences' nearly $3 billion valuation, labeling it as the biotech industry's "costliest gamble.

Aug 31, 2026, 2:51 AM ETMarketRead the original at benzinga.com

Bad for SLS

Allegations of weak trial design, governance concerns, and modeled large downside increase binary downside risk ahead of the Phase 3 REGAL readout.

SLS · SELLAS Life Sciences Group Inc.

AI read · Bad for SLS

The AI's read

BMF Capital's report presents material negative evidence: it alleges the REGAL trial's comparison group is too small, questions statistical assumptions and management, and models a large downside if the trial fails. Those charges increase binary outcome risk ahead of the Phase 3 readout. Offsetting evidence (an analyst 'buy' and heavy retail interest) is noted in the source but does not negate the report's specific methodological and governance criticisms, so the net effect is negative for SELLAS in the near term.

MAGH · Magnitude International Ltd.

AI read · Neutral

The connection

Mentioned only as a prior BMF target; the current report does not provide new, firm-specific material evidence affecting MAGH.

RVMD · Reviva Pharmaceuticals Holdings, Inc.

AI read · Neutral

The connection

Ticker is listed but not materially discussed in the source; no directional evidence is provided.

Get alerts for SLS

Follow SELLAS Life Sciences Group Inc. (SLS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SLS

Free on the App Store and Google Play, or on the web.